CIBC Private Wealth Group
BCRX icon

CIBC Private Wealth Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

CIBC Private Wealth Group’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-15,796
Closed -$201K – 603
2014
Q2 		$201K Buy
+15,796
New +$154K ﹤0.01% 595

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

CIBC Private Wealth Group's BCRX Position: Q3 2014 in Review

CIBC Private Wealth Group sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2014, closing a stake of 15,796 shares — an estimated $201K sold.

CIBC Private Wealth Group first reported a position in BCRX in Q2 2014 and held it in 1 quarter. The position peaked at $201K in Q2 2014. 102 funds tracked by Wall St. Rank hold BCRX as of Q3 2014.

  • CIBC Private Wealth Group reported no remaining BioCryst Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • CIBC Private Wealth Group sold 15,796 BioCryst Pharmaceuticals shares in Q3 2014, an estimated $201K.
  • CIBC Private Wealth Group first reported a position in BioCryst Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • CIBC Private Wealth Group's BioCryst Pharmaceuticals position peaked at $201K in Q2 2014.
  • 102 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2014.

Based on CIBC Private Wealth Group's 13F filing for Q3 2014, filed 12 Nov 2014.